[go: up one dir, main page]

WO1999036536A3 - Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial - Google Patents

Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial Download PDF

Info

Publication number
WO1999036536A3
WO1999036536A3 PCT/US1999/001087 US9901087W WO9936536A3 WO 1999036536 A3 WO1999036536 A3 WO 1999036536A3 US 9901087 W US9901087 W US 9901087W WO 9936536 A3 WO9936536 A3 WO 9936536A3
Authority
WO
WIPO (PCT)
Prior art keywords
clearance
compositions
methods
cell death
programmed cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/001087
Other languages
English (en)
Other versions
WO1999036536A2 (fr
WO1999036536A9 (fr
Inventor
Peter J Sims
Therese Wiedmer
Ji Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blood Center Research Foundation Inc
Original Assignee
Blood Center Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blood Center Research Foundation Inc filed Critical Blood Center Research Foundation Inc
Priority to AU23262/99A priority Critical patent/AU2326299A/en
Priority to EP99903179A priority patent/EP1047779A2/fr
Publication of WO1999036536A2 publication Critical patent/WO1999036536A2/fr
Publication of WO1999036536A9 publication Critical patent/WO1999036536A9/fr
Publication of WO1999036536A3 publication Critical patent/WO1999036536A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode d'accroissement de la viabilité des cellules ou des tissus mammifères, consistant à inhiber l'expression de la PL-scramblase native dans les cellules ou les tissus. Dans un autre mode de réalisation, l'invention concerne une méthode de réduction du potentiel métastatique et invasif ainsi que du potentiel de viabilité des cellules cancéreuses, des tissus cancéreux, ou des cellules infectées par virus, par l'augmentation de l'expression ou l'activité de la protéine PL-scramblase dans les cellules ou les tissus en question.
PCT/US1999/001087 1998-01-20 1999-01-19 Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial Ceased WO1999036536A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU23262/99A AU2326299A (en) 1998-01-20 1999-01-19 Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system
EP99903179A EP1047779A2 (fr) 1998-01-20 1999-01-19 Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7195098P 1998-01-20 1998-01-20
US60/071,950 1998-01-20

Publications (3)

Publication Number Publication Date
WO1999036536A2 WO1999036536A2 (fr) 1999-07-22
WO1999036536A9 WO1999036536A9 (fr) 1999-11-04
WO1999036536A3 true WO1999036536A3 (fr) 1999-12-09

Family

ID=22104619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001087 Ceased WO1999036536A2 (fr) 1998-01-20 1999-01-19 Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial

Country Status (3)

Country Link
EP (1) EP1047779A2 (fr)
AU (1) AU2326299A (fr)
WO (1) WO1999036536A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139359A1 (en) * 2001-12-04 2003-07-24 Isis Pharmaceuticals Inc. Antisense modulation of phospholipid scramblase 3 expression
US20030044979A1 (en) * 2001-04-05 2003-03-06 Isis Pharmaceuticals Inc. Antisense modulation of phospholipid scramblase I expression
IL147812A0 (en) * 2001-03-16 2002-08-14 N S T Neurosurvival Technologi Method for targeting chemical compounds to cells and pharmaceutical compositions used therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037225A1 (fr) * 1996-04-02 1997-10-09 Blood Center Research Foundation PREPARATION D'UNE PROTEINE QUI CONTROLE LE MOUVEMENT Ca2+-DEPENDANT DES PHOSPHOLIPIDES DES MEMBRANES PLASMIQUES A TRAVERS LES COUCHES DOUBLES ET INHIBITEURS DE CETTE PROTEINE
WO1999019352A2 (fr) * 1997-10-10 1999-04-22 Blood Center Research Foundation Methodes et compositions permettant de modifier l'expression de la surface cellulaire de la phosphatidylserine et d'autres phospholipides de membrane plasmique favorisant la formation de caillots

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037225A1 (fr) * 1996-04-02 1997-10-09 Blood Center Research Foundation PREPARATION D'UNE PROTEINE QUI CONTROLE LE MOUVEMENT Ca2+-DEPENDANT DES PHOSPHOLIPIDES DES MEMBRANES PLASMIQUES A TRAVERS LES COUCHES DOUBLES ET INHIBITEURS DE CETTE PROTEINE
WO1999019352A2 (fr) * 1997-10-10 1999-04-22 Blood Center Research Foundation Methodes et compositions permettant de modifier l'expression de la surface cellulaire de la phosphatidylserine et d'autres phospholipides de membrane plasmique favorisant la formation de caillots

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
B VERHOEVEN ET AL: "Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 182, no. 182, 1995, pages 1597 - 1601, XP002099796, ISSN: 0022-1007 *
BRATTON, D.: "Polyamine inhibition of transbilayer movement of plasma membrane phospholipids in the erythrocyte ghost", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 269, 9 September 1994 (1994-09-09), pages 22517 - 22523, XP002107581, ISSN: 0021-9258 *
E F SMEETS ET AL: "Calcium-induced transbilayer scrambling of fluorescent phopholipids analogs in platelets and erythrocytes", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1195, no. 1195, 1994, pages 281 - 286, XP002099795, ISSN: 0006-3002 *
STOUT J G ET AL: "Change in conformation of plasma membrane phospholipid scramblase induced by occupancy of its Ca2+ binding site.", BIOCHEMISTRY, (1998 OCT 20) 37 (42) 14860-6., XP002107584 *
UTSUGI ET AL: "Elevated Expression of Phosphatidylseine in the Outer Membrane Leaflet of Human Tumor Cells and Recognition by Activated Human Blood Monocytes", CANCER RESEARCH, vol. 51, no. 51, 1 June 1991 (1991-06-01), pages 3062 - 3066, XP002101466 *
ZHAO J ET AL: "Palmitoylation of phospholipid scramblase is required for normal function in promoting Ca2+-activated transbilayer movement of membrane phospholipids.", BIOCHEMISTRY, (1998 MAY 5) 37 (18) 6361-6., XP002107583 *
ZHAO, J. ET AL.: "Level of expression of phospholipid scramblase regulates induced movement of phosphatidylserine to the cell surface", JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 MAR 20) 273 (12) 6603-6., XP002115839 *
ZHOU Q ET AL: "Identity of a conserved motif in phospholipid scramblase that is required for Ca2+-accelerated transbilayer movement of membrane phospholipids.", BIOCHEMISTRY, (1998 FEB 24) 37 (8) 2356-60., XP002098910 *
ZHOU Q ET AL: "Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 JUL 18) 272 (29) 18240-4., XP002098868 *
ZHOU, Q. ET AL.: "Sequences of human and mouse plasma membrane PL scramblase reveal residues required for Ca2+-induced reorganization of membrane phospholipids.", MOLECULAR BIOLOGY OF THE CELL, (NOV., 1997) VOL. 8, NO. SUPPL., PAGE 292A; ABSTRACT 1693., XP002107580 *
ZWAAL, R. & SCHROIT, A.: "Pathophysiologic implications of membrane phospholipid asymmetry in blood cells", BLOOD, vol. 89, 15 February 1997 (1997-02-15), pages 1121 - 1132, XP002107582, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
EP1047779A2 (fr) 2000-11-02
WO1999036536A2 (fr) 1999-07-22
AU2326299A (en) 1999-08-02
WO1999036536A9 (fr) 1999-11-04

Similar Documents

Publication Publication Date Title
WO2000024365A8 (fr) Traitement de la peau au moyen d'adenosine ou d'un analogue d'adenosine
WO2001051633A3 (fr) Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
WO2001073032A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
EP1146046A3 (fr) Pyrophéophorbides et leur utilisation en thérapie photodynamique
WO1987002697A1 (fr) Extraction de matieres animales en utilisant des fluides supercritiques
EP1353288A3 (fr) Système de modélisation biologique hiérarchisé et procédé associé
WO1998019167A3 (fr) Gene de classe i du complexe majeur d'histocompatibilite humain a stress cellulaire regule
WO2000029002A3 (fr) Transplantation intra-uterine de cellules embryonnaires mesenchymateuses humaines
WO2000015247A8 (fr) Traitement du myelome multiple et de la resorption osseuse provoquee par le myelome au moyen d'antagonistes de l'interaction -cam-1/vla-4
IT1244879B (it) Estratti da tessuti animali, utili in terapia e in diagnostica.
BR9903750B1 (pt) utilização não terapêutica de pelo menos um extrato de rosácea do gênero sanguisorba e processo cosmético de pigmentação da pele.
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
DE69831404D1 (de) Verwendung von mindestens einem irvingia gabonensis-extrakt in kosmetischen und/oder pharmazeutischen produkten
WO1999036536A3 (fr) Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial
WO2005047469A3 (fr) Proteine isogloboside 3 synthase porcine, adnc, organisation genomique, et region regulatrice
WO2000047231A3 (fr) Nouvelle inhibition antisens de rad51
WO2003079884A3 (fr) Methodes de diagnostic et de pronostic du cancer
TW200716979A (en) Screening methods for compounds that affect melanogenesis
EP1696028A3 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer du sein
EP1046397A3 (fr) Nouvelle substance bioactivatrice
WO2001054707A3 (fr) Utilisation d'au moins un inhibiteur d'aminopeptidase
WO2001094409A3 (fr) Traitement et diagnostic du cancer du pancreas et compositions a cet effet
WO2002047534A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer des poumons
WO2001046389A3 (fr) Cellules dendritiques autologues immatures de grade clinique destinees a la vaccination de patients atteints du cancer
EP1180367A4 (fr) Desodorisants contre les odeurs de sulfures de fermentation intestinale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/20-20/20; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999903179

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09600535

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999903179

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999903179

Country of ref document: EP